Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Sotio Biotech Inc.
Pfizer
Pfizer
M.D. Anderson Cancer Center
Stanford University
Erasca, Inc.
Kaiser Permanente
Arvinas Inc.
Jonsson Comprehensive Cancer Center
Degron Therapeutics Co.
National Cancer Institute (NCI)
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Ikena Oncology
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Columbia University
Thomas Jefferson University
Theratechnologies
Xynomic Pharmaceuticals, Inc.
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Salubris Biotherapeutics Inc
ABM Therapeutics Corporation
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoffmann-La Roche
Genmab
Kineta Inc.
University Hospital, Ghent
MacroGenics
Fore Biotherapeutics
Lumos Pharma
Celgene
Celgene
Novartis
University of Chicago
Calando Pharmaceuticals
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Mannkind Corporation